We want to find better ways to support people suffering with mental health challenges, and we believe we’re onto something important.
About our Discovery Center
In August 2020, we established a Discovery Center under a sponsored research agreement with University of the Sciences in Philadelphia (USciences). We will focus on developing optimised psychedelic and related compounds targeting the 5-HT2A receptor, which is believed to mediate the potential therapeutic effects of psychedelics. We will be a joint owner and exclusive licensee for all new compounds generated during the project.
Dr Jason Wallach, Assistant Professor of Pharmaceutical Sciences at USciences, is leading the work with the COMPASS team, alongside Dr Adam Halberstadt, Associate Professor, Psychiatry, UC San Diego, School of Medicine and Dr John D McCorvy, Assistant Professor, Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin.
As part of our COMP360 psilocybin therapy development programme, we partnered with the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London to run a study with healthy volunteers.